Moving beyond cytotoxic drug dosing in ovarian cancer

Affiliations

¹ Division of Gynecologic Oncology and Center for Personalized Cancer Therapy, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Diego, Moores Comprehensive Cancer Center, La Jolla, CA 92093, USA. Electronic address: reskander@ucsd.edu.
² Division of Gynecologic Oncology and Center for Personalized Cancer Therapy, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Diego, Moores Comprehensive Cancer Center, La Jolla, CA 92093, USA.

Free article

Comment

Ramez N Eskander et al. Lancet. 2019.

Free article

. 2019 Dec 7;394(10214):2043-2045.

doi: 10.1016/S0140-6736(19)32948-4. Epub 2019 Nov 29.

¹ Division of Gynecologic Oncology and Center for Personalized Cancer Therapy, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Diego, Moores Comprehensive Cancer Center, La Jolla, CA 92093, USA. Electronic address: reskander@ucsd.edu.
² Division of Gynecologic Oncology and Center for Personalized Cancer Therapy, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Diego, Moores Comprehensive Cancer Center, La Jolla, CA 92093, USA.

No abstract available

Comment on

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA. Clamp AR, et al. Lancet. 2019 Dec 7;394(10214):2084-2095. doi: 10.1016/S0140-6736(19)32259-7. Epub 2019 Nov 29. Lancet. 2019. PMID: 31791688 Free PMC article. Clinical Trial.